eplontersen

AstraZeneca adds Latin America to Ionis ATTR partnership for $20M
AstraZeneca adds Latin America to Ionis ATTR partnership for $20M
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
Latin American
eplontersen
ATTR
Flag link:
Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam
Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam
Fierce Biotech
Ionis Pharmaceuticals
AstraZeneca
eplontersen
Alnylam
ATTR
Flag link:
Could This Rare-Disease Drug Candidate Become a Blockbuster?
Could This Rare-Disease Drug Candidate Become a Blockbuster?
Motley Fool
AstraZeneca
Ionis Pharmaceuticals
eplontersen
ATTR amyloidosis
Flag link:
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy
PR Newswire
Ionis Pharmaceuticals
FDA
eplontersen
hATTR-pn
Flag link:
AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen
AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen
Pharmaforum
AstraZeneca
eplontersen
Ionis
ATTR
Flag link:
AstraZeneca, Ionis close deal on antisense therapy development
AstraZeneca, Ionis close deal on antisense therapy development
Pharmaceutical Business Review
AstraZeneca
Ionis Pharmaceuticals
antisense
eplontersen
Flag link:
AstraZeneca wagers $200M on Ionis' next chance at a rare disease drug
AstraZeneca wagers $200M on Ionis' next chance at a rare disease drug
BioPharma Dive
AstraZeneca
Ionis Pharmaceuticals
transthyretin amyloidosis
eplontersen
Flag link: